Use of secretin in treatments of disorders associated with the amygdala
US8524665B2 · kind B2 · utility
1Cited by
10References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2004 |
| Grant date | Sep 3, 2013 |
| Priority date | — |
| Expiry date | Sep 13, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In general, the present invention provides methods for treating disorders associated with the amygdala. The methods of treatment are based on the administration of a therapeutically effective amount of secretin to an individual suffering from a disorder associated with the amygdala, e.g., bipolar disorder or a substance use disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.